Avalo Therapeutics (AVTX) Income from Continuing Operations (2014 - 2026)
Avalo Therapeutics (AVTX) posted Income from Continuing Operations of 19630000.0 for Q1 2026, down 43.08% on a QoQ basis from 13720000.0 in Q4 2025, and down 49.29% year-over-year from 38709488.6 in Q1 2025.
Avalo Therapeutics (AVTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 19630000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 49.29% year-over-year to 19630000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84740000.0 (down 216.06% YoY) and the FY2025 annual result came in at 78259000.0, down 122.78% from the prior year.
- Income from Continuing Operations was 19630000.0 for Q1 2026 at Avalo Therapeutics, down from 13720000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 98463000.0 in Q2 2024 and bottomed at 121290000.0 in Q1 2024.
- A 5-year average of 12130588.24 and a median of 12987000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 1301.79% in 2024, while the deepest fall reached 1118.38% in 2024.
- Avalo Therapeutics' Income from Continuing Operations stood at 9812000.0 in 2022, then rose by 16.75% to 8168000.0 in 2023, then tumbled by 332.65% to 35339000.0 in 2024, then jumped by 61.18% to 13720000.0 in 2025, then slumped by 43.08% to 19630000.0 in 2026.
- Business Quant data shows AVTX's Income from Continuing Operations at 19630000.0 in Q1 2026, 13720000.0 in Q4 2025, and 30625000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -19.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | -13.72 Mn |
| Sep 30, 2025 | -30.63 Mn |
| Jun 30, 2025 | -20.77 Mn |
| Mar 31, 2025 | -13.15 Mn |
| Dec 31, 2024 | -35.34 Mn |
| Sep 30, 2024 | 23.04 Mn |
| Jun 30, 2024 | 98.46 Mn |
| Mar 31, 2024 | -121.29 Mn |
| Dec 31, 2023 | -8.17 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2022 | -9.81 Mn |
| Sep 30, 2022 | 3.19 Mn |
| Jun 30, 2022 | -12.99 Mn |
| Mar 31, 2022 | -22.05 Mn |
| Dec 31, 2021 | -19.13 Mn |
| Sep 30, 2021 | -17.47 Mn |
| Jun 30, 2021 | -17.17 Mn |